The Board of Pharmacy has received notice of the following product recall:

Product	NDC Number	Lot Number	Expiration Date	Date of First Distribution
Ezetimibe 10mg Tablets – 30 bottle	0781-5690-31	JE4491	Aug-2020	01/02/2019
		JE4492	Aug-2020	01/02/2019
		JE4493	Aug-2020	01/09/2019
		JE4495	Aug-2020	01/23/2019
		JG0308	Sep-2020	03/27/2019
		JG0310	Sep-2020	02/06/2019
		JG0311	Sep-2020	02/13/2019
		JG0312	Sep-2020	03/14/2019
		JG5061	Sep-2020	03/07/2019
		JG5063	Sep-2020	02/26/2019
		JK8921	Oct-2020	04/03/2019
		JK8922	Oct-2020	04/16/2019
		JK8923	Oct-2020	04/24/2019
		JK8924	Oct-2020	05/08/2019
		JL5535	Oct-2020	05/15/2019
		JM2253	Oct-2020	05/16/2019
		JM2254	Oct-2020	05/23/2019
		JM2255	Oct-2020	06/29/2019
		JM2257	Oct-2020	05/29/2019
		JM2258	Oct-2020	06/05/2019
		JM2259	Oct-2020	06/06/2019
		JM5986	Oct-2020	06/12/2019
		JM5987	Oct-2020	06/13/2019
Ezetimibe 10mg Tablets – 90 count bottle	0781-5690-92	JE4481	Aug-2020	01/03/2019
		JG0249	Sep-2020	01/02/2019
		JK8989	Oct-2020	04/19/2019
		JN0764	Jan-2021	05/06/2019
Losartan Potassium 50mg Tablets – 30 count bottle	0781-5701-31	HV9471	Feb-2020	06/27/2018

Sandoz Inc. is recalling specific lots of 30 count and 90 count bottles of Ezetimibe 10mg Tablets and one 30 count bottle lot of Losartan Potassium 50mg Tablets distributed in the United States. This action is not a result of any quality or safety concerns with the medications for their intended use. The cap and bottle combination used to package particular lots of Ezetimibe 10mg Tablets and Losartan Potassium 50mg Tablets is not child resistant, posing a risk of harm if the tablets are swallowed by children. As a result, Sandoz is implementing a corrective action plan to the patient level in the United States.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.